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Abstract
Background: Very few studies have investigated the association between total plasma 
homocysteine (tHcy) and depressive symptoms in older Hispanics.
Objective: To test the hypothesis that high tHcy associates with depressive symptoms in older 
Hispanics.
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Methods: A total of 1,418 participants ≥ 55 years old from the Maracaibo Aging Study (MAS) 
underwent standardized neurological, neuropsychiatric, and cardiovascular assessments. The 
Neuropsychiatric Inventory Depression Subscale (NPId) was used to assess the burden of 
depressive symptoms. The tHcy levels and other biochemical parameters in blood samples were 
measured. Univariate and multivariate logistic regression models were applied.
Results: Participants with depressive symptoms had higher levels of tHcy than those without 
(15.1 versus 13.9 μmol/L; p = 0.009). Elevated tHcy levels were associated with depressive 
symptoms after adjusting for age, sex, education, smoking, diabetes, hypertension, alcohol intake, 
stroke, and dementia (OR = 1.58; 95% CI, 1.18–2.12).
Conclusion: Elevated levels of tHcy were associated with depressive symptoms in older 
Hispanics living under the nutritional and environmental conditions of a developing country.
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INTRODUCTION
Depressive symptoms are very common among older adults and are associated with 
disability and poorer health outcomes [1, 2]. High blood concentrations of homocysteine 
have been found to be associated with depressive symptoms in some studies [3–6] but not all 
[7, 8]. Homocysteine is an amino acid derived from methionine and is a key component of 
two major metabolic pathways: remethylation to methionine and transsulfuration to 
cystathionine. The first of these pathways, remethylation to methio-nine, is vitamin B-12 
dependent [9]. Once methionine is formed, the majority of it is activated to form S-
adenosylmethionine (SAM) in a folate-dependent reaction, which serves as a methyl donor 
in neurological reactions such as the synthesis of neurotransmitters, the formation of 
membrane phospholipids, and the metabolism of nucleic acids [10]. Decreased SAM leads 
to impaired synthesis of serotonin [11,12], which is an important factor in the genesis of 
depression [13] potentially explaining why individuals with depression have higher levels of 
total plasma homocysteine (tHcy).
Most studies examining the association between depression and tHcy have been performed 
in developed countries [4, 8]. The impact of the differences in nutritional contexts across 
low, middle, and high-income countries in the association between tHcy and depressive 
symptoms needs to be better understood. Ethnic differences might also play an important 
role in this association as studies in US populations had a 30% lower folate intake in 
Hispanics in contrast to White Americans [14]. We conducted this study to test the 
hypothesis that high levels of tHcy are associated with depressive symptoms in elderly 
Hispanics residing in Venezuela—a middle-income to developing country.
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This study examined a subset of participants from the Maracaibo Aging Study (MAS)—a 
population-based cohort study investigating age-related diseases among elderly residents of 
Santa Lucía, Maracaibo, Venezuela [15]. The study design and methods were described in 
detail elsewhere [16]. Briefly, the MAS enrolled approximately 2,438 participants from 1998 
until 2001 in a catchment area known as “Santa Lucía”. The clinical evaluation of each 
participant included a neuropsychiatric examination that integrated medical and family 
history with history of risk factors for dementia and depressive symptoms. The present study 
is restricted to a subset of 1,418 MAS participants who had a tHcy measurement and an 
assessment of mood and other evaluations as measured by the NPI (see below). The tHcy 
and neuropsychiatric assessments were measured the same day or the next day; in a small 
proportion of participants, these assessments were performed within one week. The 1,418 
participants included here did not differ significantly from those who were excluded except 
for age, prevalence of diabetes, and hypertension (see Supplementary Table 1). Among 
1,418 study participants, the proportion of missing values did not differ significantly 
between those with versus without depressive symptoms.
Ethical statement
The University of Zulia Institutional Ethical Review Board approved the MAS and informed 
consent was obtained from all participants.
Assessment of depressive symptoms and cognitive functions
Depressive symptoms were evaluated using the validated Spanish version of the 
Neuropsychiatric Inventory (NPI) [17, 18], the NPI depression subscale (NPId). The NPId 
rates each symptom according to frequency (0–4 points) and severity (1–3 points), and the 
total score is calculated by multiplying the frequency x severity. The possible scores from 
the NPId range from 0 to 12 points. The interpretation of the results is as follows: 0 points = 
There are no depressive symptoms; 1–3 points = mild depressive symptoms; and 4–12 points 
= clinically significant depressive symptoms. While most NPI scores were self-reported, the 
family provided the information for NPI scores for participants with dementia. Methods are 
described in detail elsewhere [16]. A diagnosis of dementia was determined by consensus in 
a diagnostic conference of physicians, psychologists, and social workers based on the 
criteria in the Diagnostic and Statistical Manual of Mental Disorders (4th edition) [19]. The 
Clinical Dementia Rating (CDR) was used to assess the dementia severity [20, 21].
Other measures
Sociodemographic variables included age, sex, and years of formal education. Potentially 
confounding medical conditions were also studied including hypertension, diabetes, stroke, 
and hyperhomocysteinemia. Hypertension was defined as having systolic blood pressure ≥ 
140 mmHg, diastolic blood pressure ≥ 90 mmHg, or current treatment with anti-
hypertensive drugs. Diabetes was defined as a serum glucose level ≥ 126 mg/dL, current 
pharmacological treatment of diabetes, or a self-reported history of diabetes. Stroke was 
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defined through self-reported diagnosis. Hyperhomocysteinemia or elevated tHcy levels 
were defined as tHcy ≥ 14 μmol/L [22]. Depressive symptoms were defined as having a cut-
off point of ≥ 4 in the NPId subscale (clinically significant depressive symptoms).
Laboratory analysis
Plasma tHcy, folate, serum glucose, cholesterol, and triglycerides were measured using 
blood samples obtained between and 7:00 and 8:00 AM after overnight fasting. All blood 
samples were obtained and processed at the Cardiovascular Center of the University of Zulia 
(CCUZ) in Maracaibo. Samples were immediately placed in crushed ice and protected from 
light and were processed within 1 h of collection. The biochemical assays for all samples 
were performed at the CCUZ, and a subset was validated at two external laboratories: The 
University of Texas Southwestern Medical School and the Instituto Venezolano de 
Investigaciones Cientificas in Caracas. The values obtained by the three laboratories were 
highly comparable—the Pearson’s correlation coefficient (r2) between absolute values from 
MAS analyses and the HPLC results from Caracas and Texas was 0.99 in each case. Details 
of sample collection and analyses have been published previously [22].
Statistical analysis
Quantitative traits between individuals with versus without depressive symptoms were tested 
using Student’s t-test. The distribution of cardiovascular risk factors was compared using the 
Pearson χ2 test. To test whether hyperhomocysteinemia (defined as tHcy ≥ 14 μmol/L) was 
associated with depressive symptoms, we applied multivariable logistic regression models. 
Because the relationships between depressive symptoms and tHcy levels could be altered by 
the presence of chronic conditions, we present three logistic multivariate models with two 
potentially confounding medical conditions, namely stroke and dementia. Model 1 adjusted 
for age, sex, level of education, smoking history, diabetes, folate, hypertension, and alcohol 
intake. Model 2 adjusted for a history of stroke as well as the covariates in Model 1. Model 3 
adjusted for a history of dementia as well as the covariates in Model 2. We first performed 
the analysis using the entire set of 1,418 individuals; we then performed an additional 
analysis stratified by age (55–66 versus > 66 years). All statistical analyses were performed 
using SPSS software version 22 (SPSS, IBM Corporation, Armonk, NY, USA).
RESULTS
Cohort characteristics
Table 1 shows the mean age of the study participants to be 66.8 years. The proportion of 
women was higher (69.3%) than that of men. Men were slightly younger than women and 
had higher levels of education. This study includes a subset of MAS study participants who 
had both levels of tHcy and NPId measured at one time point, differences with MAS 
participants excluded from this analysis are presented in Supplementary Table 1.
The prevalence of individuals diagnosed with clinically significant depressive symptoms by 
NPId was 16.7% (Table 1). The group with depressive symptoms had a significantly higher 
mean age, higher percentage of women, lower average years of education, and higher 
illiteracy rate than the group without depressive symptoms (Table 1). The individuals with 
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depressive symptoms had a significantly higher prevalence of diabetes (15.0 versus 10.7%), 
stroke (10.1 versus 5.0%), and dementia (15.2 versus 5.1%). Individuals with depressive 
symptoms were less likely to be currently exposed to smoking and alcohol than those 
without depressive symptoms.
Homocysteine and depressive symptoms
Individuals with depressive symptoms were more likely to have hyperhomocysteinemia than 
those without depressive symptoms (49.8 versus 36.8%, χ2 = 13,927; p < 0.0001). In 
addition to having significantly higher mean tHcy levels (15.1 versus 13.9 μmol/; p = 0.009), 
individuals with depressive symptoms had higher levels of cholesterol and triglycerides but 
had lower levels of folate than those without depressive symptoms.
Hyperhomocysteinemia associated with depressive symptoms
Hyperhomocysteinemia was associated with a 1.71-fold (CI, 1.30–2.28; p < 0.001) increase 
in the probability of having depressive symptoms after controlling for potential confounders, 
namely, age, sex, education, smoking and alcohol exposure, presence of hypertension and 
diabetes, and folate levels (Model 1, Table 2). When a history of stroke was added to the 
model (Model 2), the odds ratio declined slightly to 1.68 (CI, 1.26–2.25); p = 0.001). With 
the further addition of dementia (Model 3), the odds ratio further reduced to 1.57 (CI, 1.17–
2.09; p = 0.002).
To account for the fact that levels of tHcy increase with age, we performed a stratified 
analysis by age using the same three models above (Table 2). The effect of 
hyperhomocysteinemia was slightly stronger in the younger age group (55–66 years) than in 
the older group (>66 years) after controlling for potential confounders: age, sex, education, 
smoking and alcohol exposure, presence of hypertension and diabetes, and folate levels 
(Model 1, Table 2). When a history of stroke was added to the model, the odds ratio declined 
slightly in both groups (Model 2). With further addition of dementia, the odds ratio for 
depressive symptoms was relatively constant in the younger group (Model 3); however, the 
odds ratio for the older group was reduced and was no longer statistically significant.
Model performance
The inclusion of hyperhomocysteinemia significantly improved the model performance in a 
basic model accounting for sex, age, education, current smoking, diabetes, hypertension, 
alcohol intake, stroke, and dementia in the study sample, and in subjects 55–66 years old 
(Table 3). The basic model accounted for 4.91% to 5.95% of the model performance (p < 
0.001) in the study sample and stratified by age groups. When hyperhomocysteinemia was 
included, the model performance improved 0.68% (p = 0.002) in the study sample, and 
1.61% (p = 0.001) and 0.53% (p = 0.052) among subjects 55–66 and > 66 years old, 
respectively.
DISCUSSION
The present study of the MAS cohort showed that individuals with depressive symptoms had 
significantly higher mean tHcy levels and a higher proportion of hyperhomocysteinemia 
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than individuals without depressive symptoms. This study provides the first evidence that 
elevated tHcy is associated with depressive symptoms in Hispanics living under the 
nutritional and environmental conditions of Latin America. Our findings agree with previous 
studies of older adults residing in developed countries [23, 24]. The relationship between 
elevated tHcy levels and depressive symptoms is complex because there are health 
conditions associated with depression such as stroke [25], dementia [26], and diabetes [27]. 
The tHcy levels vary with sex and age [28] and are influenced by diet (including 
supplementation of folate and others vitamins), lifestyle, health status, and genetic factors 
[29]. Furthermore, late-life depression or depressive symptoms in the elderly are associated 
with cerebrovascular disease, poor health status, diabetes, dementia, and genetic factors [29] 
as well as psychosocial risk factors including personality disorders and personality attributes 
[30]. Here, we accounted for those potential factors in the adjusted logistic regression 
models. When the sample was stratified by age groups (Model 1), hyperhomocysteinemia 
only remained significantly associated to depressive symptoms in subjects 55–66 years old.
We found a significantly higher prevalence of stroke in subjects with depressive symptoms 
than in those without depressive symptoms corroborating the results of previous studies that 
showed that cerebrovascular disease and stroke are associated with depression or depressive 
symptoms [25]. After adjustment by stroke (Model 2), hyperhomocysteinemia remained 
significantly related to depressive symptoms. These results suggest that the effects of 
hyperhomocysteinemia on depressive symptoms are independent of stroke especially in the 
younger group. Further studies need to address the effectiveness of monitoring and reducing 
tHCY levels in middle age as a preventive measure of depressive symptoms in populations at 
high risk of depression such as Hispanics.
The prevalence of dementia was significantly higher in subjects with depressive symptoms 
than in those without depressive symptoms in agreement with previous findings [31]. 
Elevated tHcy was associated with depressive symptoms after adjustment for dementia 
(Model 3) in all subjects and in the group of subjects aged 55–66 years old suggesting that 
the effects of hyperhomocysteinemia on depressive symptoms are independent of dementia
—especially in the younger group. Our findings of the association of hyperhomocysteinemia 
with a 1.58-fold increase in the probability of having depressive symptoms after controlling 
for confounding factors is similar to the findings of some previous studies where the odds 
ratio ranged from a 1.26 to 1.90-fold increase [4, 5]. The significant but relatively modest 
associations between depressive symptoms and elevated Hcy levels in these studies might 
explain the discrepancies between other previous studies that are smaller than the MAS.
The incremental value of hyperhomocysteinemia as a marker for depressive symptoms is 
significant in this population, particularly among those participants in the younger group 
(55–66 years). Even if the effect size of high levels of tHcy is small (Table 3) and clinical 
relevance uncertain, adding a marker related to depressive symptoms to the prediction 
models containing standard risk factors might lead to improved quantification of true future 
risk of developing depression. Longitudinal studies are needed to test the implications of this 
study.
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Some limitations in our study are recognized and need to be discussed. First, this study used 
cross-sectional data; therefore, it was not possible to determine if the elevated levels of 
homocysteine preceded the depressive symptoms or other medical conditions including 
stroke, dementia, and diabetes. Second, given the participants excluded from the analysis 
(that were older and with more chronic illness), our results are likely to underestimate the 
degree of association between depressive symptoms and tHcy. Another potential limitation 
in our study was that our clinical definition of stroke was based on self-reports not 
accounting for “silent” cerebrovascular disease only detectable by brain imaging; therefore, 
the prevalence of cerebrovascular disease was likely underestimated [32]. Finally, the NPId 
does not diagnose depressive disorders according the DSM-5. The main strength of our 
study is the inclusion of older Hispanics residing in their country of origin in Latin America, 
because these subjects live under unfavorable nutritional and environmental conditions that 
might contribute to increased Hcy levels in contrast to other older adults residing in 
developed countries [22, 32]. A previous study of tHcy and depressive symptoms in older 
Latinas residing in Sacramento, California, focused on the relationship between folate levels 
and depressive symptoms [33], and tHcy was not associated with depressive symptoms. 
Earlier studies of the relationship between tHcy and depressive symptoms included diverse 
ethnic groups with varying environmental exposures and had inconsistent results [6, 34].
CONCLUSIONS
This study suggests that elevated tHCY independently associates with depressive symptoms 
in elderly Latin Americans. Although longitudinal data are needed to assess causality, the 
demonstrated relationship between tHcy and depressive symptoms in this Latin American 
population provides new insights into the relevance of hyperhomocysteinemia throughout 
life and particularly for depressive symptoms in populations from developing countries 
where hyperhomocysteinemia is common.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 3
Nested Logistic Regression Models Relating Depressive Symptoms with Hyperhomocysteinemia
Models χ2 Statistic p R2 (%)‡
Study sample
 Base model* 86.5 <0.001 5.92
 +Hyperhomocysteinemia 96.0 0.002 0.68%
Subjects 55–66 years
 Base model* 35.2 <0.001 4.91%
 +Hyperhomocysteinemia 46.6 0.001 1.61%
Subjects>66 years
 Base model* 44.0 <0.001 5.95%
 +Hyperhomocysteinemia 47.8 0.052 0.53%
*
Base model accounted for age, sex, education, current smoking, diabetes, hypertension, alcohol intake, stroke, and dementia.
‡
R2 is an estimate of the additional variance explained (https://apha.confex.com/apha/134am/techprogram/paper_135906.htm).
J Alzheimers Dis. Author manuscript; available in PMC 2021 July 23.
